[6-K] Clearmind Medicine Inc. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Clearmind Medicine Inc. (CMND) filed a Form 6-K to furnish a press release announcing that its Data and Safety Monitoring Board unanimously approved continuation of its Phase I/IIa clinical trial for CMND-100 following a positive interim safety review. This indicates that an independent board reviewed early safety data for CMND-100 and supported ongoing dosing in the current trial stage. The first four paragraphs of this press release are also incorporated by reference into Clearmind’s existing Form F-3 and Form S-8 registration statements, linking this clinical update directly into its U.S. securities offering documents.

Insights

Biotech clinical development analyst

Positive interim safety review allows Clearmind to keep advancing CMND-100’s early-stage trial.

Clearmind Medicine reports that its Data and Safety Monitoring Board unanimously approved continuation of the Phase I/IIa trial for CMND-100 after a positive interim safety review. A DSMB is an independent group that evaluates patient safety data and can recommend pausing or stopping a study if concerns arise, so unanimous support is a constructive signal for the program’s current dosing and design.

The trial remains early stage, and the update focuses on safety rather than efficacy, so long-term outcomes for CMND-100 are still uncertain. Clearmind is also incorporating the first four paragraphs of this press release into its existing Form F-3 and Form S-8 registration statements, ensuring this clinical safety information is reflected in its U.S. offering materials. Subsequent clinical updates and future filings will be important to understand how CMND-100 progresses beyond this interim milestone.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: November 2025

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on November 24, 2025, titled “Clearmind Medicine’s Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review”.

The first four paragraphs of the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Clearmind Medicine’s Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Clearmind Medicine, Inc.
	(Registrant)
Date: November 24, 2025	By:	/s/ Adi Zuloff-Shani
	Name:	Adi Zuloff-Shani
	Title:	Chief Executive Officer

3

FAQ

What did Clearmind Medicine (CMND) announce in this Form 6-K?

Clearmind Medicine furnished a press release stating that its Data and Safety Monitoring Board unanimously approved continuation of the Phase I/IIa clinical trial for CMND-100 following a positive interim safety review.

What is the significance of the positive interim safety review for CMND-100?

A positive interim safety review by an independent Data and Safety Monitoring Board means current safety data for CMND-100 in the Phase I/IIa trial were acceptable, allowing the study to continue as planned.

Which clinical trial phase is CMND-100 currently in according to the filing?

The filing refers to an ongoing Phase I/IIa clinical trial for CMND-100, indicating an early-stage study that combines initial safety assessment with early signals in patients.

How does this 6-K relate to Clearmind Medicine’s shelf and equity plans?

The first four paragraphs of the press release are incorporated by reference into Clearmind’s existing Form F-3 registration statements (File Nos. 333-275991, 333-270859, 333-273293) and its Form S-8 registration statement (File No. 333-283695).

Does this Form 6-K itself register or sell new securities for CMND?

This Form 6-K furnishes information and incorporates parts of the press release into existing registration statements. It does not, by itself, describe a new securities sale.

Who signed the Form 6-K for Clearmind Medicine and in what capacity?

The Form 6-K was signed by Adi Zuloff-Shani in the capacity of Chief Executive Officer of Clearmind Medicine Inc.